Tony Mok, MD
The investigational second-generation tyrosine kinase inhibitor (TKI) dacomitinib improved overall survival (OS) compared with gefitinib as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR
mutations. Median OS was 34.1 months in patients randomized to dacomitinib versus 26.8 months in those randomized to gefitinib (Iressa), according to the open-label, phase III ARCHER 1050 study presented at the 2018 ASCO Annual Meeting.1
With a median duration follow-up of 31.1 months, the data provide the first evidence of an OS advantage in a randomized direct comparison of 2 EGFR TKIs as first-line therapy for EGFR
Based on the finding, “dacomitinib should be considered as a new treatment option for first-line management of patients with EGFR
mutation-positive advanced NSCLC,” said presenter Tony Mok, MD, professor and chair of the Department of Clinical Oncology, Chinese University of Hong Kong.
... to read the full story